|
1
|
Fallah M, Liu X, Ji J, Försti A, Sundquist
K and Hemminki K: Autoimmune diseases associated with non-Hodgkin
lymphoma: A nationwide cohort study. Ann Oncol. 25:2025–2030. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Váróczy L, Gergely L, Zeher M, Szegedi G
and Illés A: Malignant lymphoma-associated autoimmune diseases-a
descriptive epidemiological study. Rheumatol Int. 22:233–237. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park SY, Kim S, Kim ES, Choi SU, Hyun HJ,
Ahn JY, Lee JH, Ryu SH, Park JH, Lee GI and Lee HJ: A case of
Non-Hodgkin's lymphoma in patient with coombs' negative hemolytic
anemia and idiopathic thrombocytopenic purpura. Cancer Res Treat.
44:69–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Michel M, Chanet V, Dechartres A, Morin
AS, Piette JC, Cirasino L, Emilia G, Zaja F, Ruggeri M, Andrès E,
et al: The spectrum of Evans syndrome in adults: New insight into
the disease based on the analysis of 68 cases. Blood.
114:3167–3172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rummel MJ, Niederle N, Maschmeyer G, Banat
GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M,
Balser C, et al: Bendamustine plus rituximab versus CHOP plus
rituximab as first-line treatment for patients with indolent and
mantle-cell lymphomas: An open-label, multicentre, randomised,
phase 3 non-inferiority trial. Lancet. 381:1203–1210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iannitto E and Tripodo C: How I diagnose
and treat splenic lymphomas. Blood. 117:2585–2595. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishii-Ito S, Izumi H, Touge H, Takeda K,
Hosoda Y, Yamasaki A, Kuwamoto S, Shimizu E and Motokura T:
Pulmonary intravascular large B-cell lymphoma successfully treated
with rituximab, cyclophosphamide, vincristine, doxorubicin and
prednisolone immunochemotherapy: Report of a patient surviving for
over 1 year. Mol Clin Oncol. 5:689–692. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yousem SA and Colby TV: Intravascular
lymphomatosis presenting in the lung. Cancer. 65:349–353. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mahevas M, Gerfaud-Valentin M, Moulis G,
Terriou L, Audia S, Guenin S, Le Guenno G, Salles G, Lambotte O,
Limal N, et al: Characteristics, outcome, and response to therapy
of multirefractory chronic immune thrombocytopenia. Blood.
128:1625–1630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hitz F, Zucca E, Pabst T, Fischer N,
Cairoli A, Samaras P, Caspar CB, Mach N, Krasniqi F, Schmidt A, et
al: Rituximab, bendamustine and lenalidomide in patients with
aggressive B-cell lymphoma not eligible for anthracycline-based
therapy or intensive salvage chemotherapy-SAKK 38/08. Br J
Haematol. 174:255–263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohmachi K, Niitsu N, Uchida T, Kim SJ,
Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, et al:
Multicenter phase II study of bendamustine plus rituximab in
patients with relapsed or refractory diffuse large B-cell lymphoma.
J Clin Oncol. 31:2103–2109. 2013. View Article : Google Scholar : PubMed/NCBI
|
